However, co-infusion of CD4 T-cells expressing another TCR that is able to mediate cytokine release upon encountering AML cells or peptide vaccination may be considered to stimulate the in-vivo expansion and survival of CD8 T-cells and, thereby, the capacity of the dNPM1 HLA-A11 TCR to induce an anti-tumor response. The gene discussed is CD8A; the disease is acute myeloid leukemia.